Tests cord blood platelet plasma eye injections for dry macular degeneration
Tests eye injections of cord blood platelet plasma in older adults with dry AMD.
Plain-language title generated from the registry record
Registry title: Age-related Macular Degeneration of Atrophic Type Treated With Umbilical Cord Blood Enriched With Platelet Plasma.
Key facts
- Where
- Rome, ItalySee the site
Where in Italy
- Fondazione Policlinico Universitario Agostino Gemelli IRCCSRome, ItalyTaking people
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Trial details
- Who runs it
- Fondazione Policlinico Universitario Agostino Gemelli IRCCS
- Trial code
- NCT06536062
- Record updated
- 23 September 2025
- Original description
The objective of the study will be to evaluate the efficacy of intravitreal injections of Umbilical Cord Blood Platelet-rich Plasma (CB-PRP) in order to reduce or stabilize the atrophic progression in dry Age-related Macular Degeneration (AMD).Read full original descriptionShow less
Age-related Macular Degeneration of Atrophic Type Treated With Intravitreal Injection of Umbilical Cord Blood Enriched With Platelet Plasma: Multicenter Study.
The objective of the study will be to evaluate the efficacy of intravitreal injections of Umbilical Cord Blood Platelet-rich Plasma (CB-PRP) in order to reduce or stabilize the atrophic progression in dry Age-related Macular Degeneration (AMD).
Inclusion: Age ≥65 years; Bilateral dry-AMD; ETDRS-corrected visual acuity between (or equal to) 1/10 and 4/10; No concomitant ocular pathology (e.g., Glaucoma, amblyopia) or systemic pathology that would result in a BIAS for primary goal assessment; Signature of informed consent.
Exclusion: Previous inflammatory/infectious events involving the eyes; Previous intravitreal treatments; Eye trauma, diabetes, or disease potentially damaging to the visual system, even in the absence of impairment at the time of intake; Age < 65 years; Pregnancy; Refusal to sign informed consent.